Just a few weeks after issuing a Drug Safety Communication over an increased risk of amputations while taking Invokana (canagliflozin), the Food and Drug Administration (FDA) recently issued another Safety Announcement for the type 2 diabetes drug warning patients make be at risk for acute kidney injuries. This brings the total number of safety announcements to nearly half a dozen over the last year.
The FDA warns Invokana patients acute kidney injuries may result in the kidneys ceasing to function, causing a buildup of dangerous waste material. Patients experiencing symptoms of acute kidney injuries like swelling of the hands or feet or decreased urine should immediately seek medical attention.
Federal regulators received over 100 reports of patients suffering acute kidney injuries while taking SGLT2 inhibitors like Invokana. According to the FDA announcement, over half of these injuries occurred within one month of patients taking the drug. Almost every single one of them required hospitalization to manage treatment for their renal condition induced while taking Invokana.
Tragically, an estimated 20 percent of those hospitalized with these acute kidney injuries ended up in intensive care, resulting in four deaths. 10 percent of the 101 patients did not recover from their acute kidney injuries and saw a change in their renal function.
If you or a loved one suffered a serious injury like kidney failure, heart attack, stroke, bone fracture, or diabetic ketoacidosis, it could be because Johnson & Johnson knew or should have known of the risks the type 2 diabetes drug posed but failed to warn users. While J&J spends millions of dollars promoting its breakthrough drug, hundreds and perhaps thousands of patients suffer from possible side effects of Invokana.
At The Cochran Firm, D.C. we hold powerful corporations like J&J responsible for their careless actions and putting profits before people. Contact us for a free legal consultation about your Invokana kidney injury.
